Nikolaj Skak

Nikolaj Skak is the current CTO and Founder at Biograil. Prior to this, they were the Director of Pharmaceutical Development at Egalet Corporation from January 2012 to January 2020. In this role, they were responsible for lean and efficient formulation development of key company product candidates from pre-clinical to late clinical stages, and commercialization of Arymo ER (oral tablet). Nikolaj was also successful in transferring a novel technology for establishment of commercial manufacturing at an international CMO.

Skak has a long history of success in the pharmaceutical industry. Nikolaj began their career as a Project Manager, successfully managing projects to clinical phase 1, including portfolio projects, external collaborations with companies in the US/Japan, and a portfolio project developed externally at CDMO in the US. Nikolaj then transitioned into Department Manager, where they successfully brought several product candidates from pre-clinical into late clinical stages, and to regulatory approval of a NDA.

Throughout their career, Skak has demonstrated their ability to drive innovation and create value. Nikolaj has a proven track record of success in both small and large organizations, making him an ideal candidate for their current role as CTO & Founder at Biograil.

Nikolaj Skak has a MSC in Pharmaceutical Sciences from Københavns Universitet - University of Copenhagen and an ACDRS from University of California, San Francisco.

Their manager is Karsten Lindhardt, CEO & Founder. They work with Nils Piwon - Chief Development Officer, Martin Rex Olsen - Manufacturing Director.